Keeps Pricing Analysis & Total Cost: What You Actually Pay for Hair Loss Treatment

What Keeps Actually Charges

Keeps operates as a direct-to-consumer subscription service for androgenetic alopecia treatment in men. The two core medications it prescribes, finasteride 1 mg (oral) and minoxidil 5% (topical), are both available as generics. Your plan cost depends on which drugs you select and whether you pay monthly or commit to a longer billing cycle.

A finasteride-only subscription runs approximately $25 per month on a monthly plan, dropping closer to $17 to $20 per month on an annual commitment. Topical minoxidil alone sits around $10 to $15 per month. Combination plans bundling both medications typically fall between $30 and $45 per month. Keeps also sells a ketoconazole shampoo add-on for roughly $9 to $12 per month, which it markets as a "thickening" product. Ketoconazole 2% shampoo has shown modest antifungal and anti-inflammatory effects on the scalp in small studies, though its independent effect on hair regrowth remains limited compared to finasteride or minoxidil [1].

These prices include the telehealth consultation. There is no separate visit fee. That bundling makes the sticker price appear reasonable until you compare it to what the same medications cost at a brick-and-mortar pharmacy.

How Keeps Pricing Compares to Retail Pharmacy Costs

The most important comparison is simple. Generic finasteride 1 mg, filled at a retail pharmacy with a discount card such as GoodRx, costs between $5 and $15 for a 30-day supply at most major chains including CVS, Walgreens, and Costco [2]. That means the drug itself may cost $60 to $180 per year. Keeps charges $200 to $300 per year for the same molecule at the same dose.

The price gap narrows somewhat when you factor in the cost of a physician visit. A dermatology consultation for hair loss, if you lack insurance or have a high deductible, could cost $150 to $300 out of pocket. Keeps eliminates that visit by embedding asynchronous telehealth review into the subscription. For a man who would otherwise pay full price for a specialist visit plus pharmacy costs, Keeps may break even or come close in the first year.

Over-the-counter minoxidil 5% tells a similar story. Kirkland Signature minoxidil (the Costco generic) runs approximately $6 to $8 per month when purchased in bulk. Keeps charges a premium over that baseline. The convenience of doorstep delivery and a unified dashboard for tracking treatment accounts for some of that markup, but the active ingredient is identical [3].

A useful cost framework: calculate your "Keeps premium" by subtracting what you would pay for the same generics at a retail pharmacy plus one annual telehealth or in-person visit. For most men, that premium falls between $100 and $250 per year. Whether that premium buys enough convenience to justify itself is a personal calculation, not a medical one.

Clinical Evidence Behind What Keeps Prescribes

Keeps does not manufacture proprietary drugs. It prescribes FDA-approved generics. The clinical evidence supporting these medications is strong and independent of any telehealth brand.

Finasteride 1 mg received FDA approval for male pattern hair loss in 1997. The registration trials enrolled 1,553 men aged 18 to 41 with mild to moderate vertex hair loss. At 2 years, men taking finasteride 1 mg daily showed a mean increase of 138 hairs in a 1-inch diameter target area, compared to a mean decrease of 38 hairs in the placebo group [4]. The 5-year extension data, published by Kaufman et al., demonstrated that 48% of men treated with finasteride were rated as having increased hair growth at year 5, and an additional 42% were rated as having no further loss [5]. That gives finasteride a 90% "responder" rate by the combined metric of maintenance plus visible improvement.

Minoxidil 5% topical solution is the other pillar. A 48-week randomized trial by Olsen et al. (N=393) found that 5% minoxidil produced 45% more hair regrowth than the 2% formulation, with the higher concentration reaching statistical significance as early as week 8 [6]. Minoxidil works through a different mechanism than finasteride. It is a vasodilator that prolongs the anagen (growth) phase of the hair cycle, while finasteride inhibits the 5-alpha-reductase enzyme that converts testosterone to dihydrotestosterone (DHT) [7].

The American Academy of Dermatology (AAD) guidelines list both finasteride 1 mg daily and topical minoxidil 5% twice daily as first-line treatments for androgenetic alopecia in men [8]. No telehealth platform changes the pharmacology. The question is whether you need a subscription service to access these drugs.

Keeps vs. Competitor Telehealth Platforms

Keeps is not the only direct-to-consumer option. Hims, Ro (Roman), and several newer entrants sell identical or near-identical medication regimens through similar subscription models. Pricing across these platforms has converged over the past several years.

Hims offers finasteride starting around $25 to $30 per month, with combination plans reaching $50 or more when topical finasteride/minoxidil sprays are included. Roman (now Ro) prices finasteride at approximately $20 to $30 per month depending on billing commitment. Both include telehealth consultations in the subscription price, mirroring the Keeps model.

Where these platforms differ is in product differentiation strategy, not in the underlying pharmacology. Hims has pushed compounded topical finasteride/minoxidil combinations, which carry higher price points ($40 to $60 per month) but have thinner clinical trial data compared to the separately studied oral finasteride and topical minoxidil regimens. Keeps has historically emphasized the standard FDA-approved formulations, which could be viewed as a more conservative and evidence-aligned approach.

Dr. Antonella Tosti, a dermatologist at the University of Miami and author of over 700 peer-reviewed papers on hair disorders, has noted: "The most important factor in hair loss treatment is starting early and staying consistent. The delivery model matters less than adherence." This observation applies directly to the Keeps versus competitor question. The AAD's clinical guidelines do not differentiate by dispensing channel [8].

One practical consideration: all of these platforms require ongoing subscriptions to maintain access. Stopping finasteride leads to resumption of hair loss within 6 to 12 months, as demonstrated in the discontinuation arms of the original registration trials [5]. That makes the long-term cost trajectory more important than the monthly snapshot.

Hidden Costs and Subscription Mechanics

Subscription models create friction around cancellation. Keeps allows users to pause or cancel online, but the process requires navigating account settings rather than a single click. Refunds on shipped and opened products are generally not available. Annual plans, while cheaper per month, lock in a larger upfront payment that may not be fully refundable if you stop treatment at month four.

Shipping is typically free within the continental United States. There is no additional charge for the initial telehealth consultation or follow-up check-ins, which occur at intervals determined by the prescribing clinician (usually every 3 to 6 months). These check-ins are asynchronous. You upload photos and answer questions through the app. A provider reviews your case and adjusts the plan if needed.

Lab work is not included. This matters because the Endocrine Society recommends baseline and periodic monitoring of liver function and PSA in men on 5-alpha-reductase inhibitors, depending on age and risk profile [9]. If your primary care physician orders these labs, insurance may cover them. If you go through a standalone lab service, expect to pay $30 to $100 per panel. Keeps does not currently bundle or subsidize lab work, and neither do most of its competitors.

The other hidden cost is opportunity cost. A man who uses Keeps exclusively may miss a dermatology evaluation that identifies a non-androgenetic cause of hair loss, such as alopecia areata, telogen effluvium from thyroid dysfunction, or nutritional deficiency. The American Academy of Dermatology recommends in-person evaluation with dermoscopy for any hair loss that does not follow a classic male pattern distribution [8]. Telehealth photo review has limitations that an in-person scalp examination does not.

Who Gets Real Value from Keeps

The subscriber who benefits most from Keeps fits a specific profile. He has classic Norwood II to IV pattern hair loss, no history of adverse reactions to finasteride, lives in an area where dermatology wait times exceed 2 to 3 months, and values the convenience of automatic refills enough to pay a moderate premium over pharmacy pricing.

Men who already have a prescribing physician and access to a pharmacy with competitive generic pricing will likely save money by filling finasteride and buying OTC minoxidil independently. A 90-day supply of generic finasteride from Costco pharmacy, for example, can cost under $15 total, which undercuts Keeps by a wide margin [2].

The FDA label for finasteride 1 mg specifies that clinical trial efficacy was established in men aged 18 to 41 with mild to moderate hair loss at the vertex and anterior mid-scalp [10]. Men with more advanced loss (Norwood V and above) showed lower response rates in post-marketing analyses. Keeps does not always make this distinction explicit in its marketing. A 2019 systematic review published in the Journal of the American Academy of Dermatology, pooling data from 12 randomized controlled trials (N=3,927), confirmed that finasteride's benefit is greatest when initiated early in the course of androgenetic alopecia [11].

Side Effect Profile and Informed Consent

Any honest pricing analysis must account for the risk side of the equation. Finasteride 1 mg carries a well-documented adverse effect profile. In the key trials, 3.8% of men on finasteride reported sexual side effects (decreased libido, erectile dysfunction, or decreased ejaculate volume) compared to 2.1% on placebo [4]. The difference is real but modest.

Post-marketing reports of persistent sexual dysfunction after finasteride discontinuation (sometimes called "post-finasteride syndrome") have generated significant attention. A 2019 pharmacovigilance study using the FDA Adverse Event Reporting System identified disproportionate reporting of persistent sexual, neurological, and psychological symptoms [12]. The FDA updated the finasteride label in 2012 to include warnings about libido disorders, ejaculation disorders, and orgasm disorders that may persist after drug discontinuation [10].

Keeps provides informed consent documentation through its telehealth platform. The depth of that counseling depends on the individual prescriber. Patients should ensure they understand these risks before committing to a subscription, regardless of which telehealth brand they use.

Minoxidil's side effect profile is milder. Contact dermatitis occurs in approximately 5% to 7% of users, primarily attributed to the propylene glycol vehicle rather than the active ingredient [6]. Foam formulations, which eliminate propylene glycol, reduce this risk. Minoxidil can also cause hypertrichosis (unwanted facial hair growth) in a small percentage of men who apply it to the scalp, likely through systemic absorption.

The Bottom Line on Value

Keeps sells convenience and brand packaging around two well-studied generic medications. The drugs work. The pricing carries a premium over retail pharmacy alternatives that ranges from modest to substantial depending on your baseline access to healthcare.

For a man who would otherwise not seek treatment at all, Keeps removes barriers. That has real clinical value, given that finasteride efficacy declines the longer treatment is delayed. The 5-year data from Kaufman et al. showed that men who started finasteride in year 3 of the trial (after crossing over from placebo) never fully caught up to men who began treatment at baseline [5]. Early initiation is the single strongest predictor of long-term hair retention, and a subscription model that accelerates access may justify its cost premium for the right patient.